PURPOSE: To evaluate subfoveal choroidal thickness in patients with central retinal vein occlusion (CRVO) using enhanced depth imaging (EDI) optical coherence tomography (OCT). DESIGN: Retrospective observational study.
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INTRODUCTION
Central retinal vein occlusion (CRVO) is a common cause of unilateral visual loss, and macular edema is a frequent cause of vision loss. Although it is well known that central macular thickness increases because of severe macular edema in CRVO, we could find no report on subfoveal choroidal thickness in patients with CRVO. Spaide and associates used spectral-domain optical coherence tomography (OCT) and developed a method termed enhanced depth imaging (EDI) OCT that enables in vivo cross-sectional imaging of the choroid and measurement of the thickness of the choroid. 1 Subsequently, the subfoveal choroidal thickness of patients with various diseases, such as central serous chorioretinopathy, 2-4 macular hole, 5 age-related macular degeneration, 6-9 high myopia, 10,11 and Vogt-Koyanagi-Harada disease, 12 was reported. Further, certain reports noted changes in subfoveal choroidal thickness after treatment. 4, 7, [11] [12] [13] [14] Because macular edema in patients with CRVO appears to be closely related to vascular endothelial growth factor (VEGF) levels in the vitreous, 15, 16 inhibiting VEGF appears to be a reasonable therapeutic approach. [17] [18] [19] Although many studies have reported that central macular thickness in CRVO decreases after anti-VEGF treatment, such as intravitreal bevacizumab therapy, we could find no reports of changes in choroidal thickness in CRVO patients after treatment. The aim of this study was to compare the choroidal thickness in the macular area between eyes with CRVO and unaffected fellow eyes and to investigate how subfoveal choroidal thickness changes after intravitreal bevacizumab.
METHODS
A retrospective analysis was performed for consecutive patients examined with unilateral CRVO at our retinal outpatient department in the Department of Ophthalmology of the University of Nagasaki from July 2010 through May 2012.
The clinical examination for diagnosis of CRVO included measurement of best-corrected visual acuity (BCVA), slit-lamp biomicroscopy with a contact lens or noncontact lens, indirect ophthalmoscopy, digital fluorescein angiography 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 Measurements of choroidal thickness and retinal thickness were analyzed using Student t -test. Spearman's rank correlation coefficient was used to evaluate the correlation between choroidal thickness of the CRVO eyes and that of the fellow eyes. For all tests, P < .05 was considered significant.
RESULTS
There were 36 patients with unilateral CRVO; their mean age was 66 ± 15 years (range, 26-84 years). Twenty-six patients (72%) were women. The type of CRVO was ischemic in 10 (28%) patients and non-ischemic in 26(72%). These   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 Table 1 . A negative correlation was found between subfoveal choroidal thickness and axial length in the CRVO eyes (r = .28, P < .05).
Compared with fellow-eyes, the CRVO eyes showed significantly greater subfoveal choroidal thickness (P < .01, paired t-test). The mean ± SD subfoveal choroidal thickness was 257.1 ± 83.2 μm in the CRVO eyes and 222.6 ± 67.8 μm in the fellow eyes ( Figure 1) . A strong correlation was found between subfoveal choroidal thickness in the CRVO eyes and that in the fellow eyes (r = .79, P < .01). The mean subfoveal choroidal thickness was 252.6 μm (ischemic) and 258.8 μm (non-ischemic) in the CRVO eyes and 217.6 μm (ischemic) and 224.5 μm (non-ischemic) in the fellow eyes. Similarly CRVO eyes showed significantly greater subfoveal choroidal thickness (P < .01, paired ttest) in both the ischemic and non-ischemic groups. There was no difference between the ischemic and non-ischemic groups. Figure 2 shows EDI-OCT images of the choroid of 1 eye with CRVO and that of the unaffected fellow eye.
For CRVO eyes, subfoveal choroidal thickness was significantly greater before intravitreal bevacizumab therapy than after therapy (P < .01, paired t-test). The mean ± SD subfoveal choroidal thickness in the CRVO eyes was 266.9 ± 79.0 μm before intravitreal bevacizumab and 227.7 ± 65.1 μm after intravitreal bevacizumab ( Figure 3) . Similarly, there was no difference between the ischemic and non-ischemic groups, and subfoveal choroidal thickness after intravitreal bevacizumab significantly decreased in both the ischemic (210.3 from 251.5μm) and non-ischemic (237.6 from 275.7 μm) groups (P < .05, paired t-test). Figure   4 shows EDI-OCT images of the choroid of 1 eye with CRVO before and after intravitreal bevacizumab treatment. 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 and 222.6 μm, respectively) in our study was less than that in the previous study, 20 this difference between the studies may have been caused by differences in the measurement software, the OCT light source, the patient profile (e.g., age). Maruko et al 3, 4 performed ICGA and found that subfoveal choroidal thickness in the fellow eyes of patients with central serous chorioretinopathy was increased in the eyes with choroidal vascular hyperpermeability. They suggested that hyperpermeability causes choroidal thickening through accumulation of fluid and that dilation of choroidal vessels plays a partial role in the choroidal thickening. In our study, we performed ICGA in certain cases; however, choroidal hyperpermeability was not clearly demonstrated. Therefore, increased subfoveal choroidal thickness may be related to not only choroidal hyperpermeability but also another cause. Choroidal blood flow is the highest of any tissue in the body to satisfy the normal metabolic 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 6 demands of the outer retina. 21 CRVO patients may be experiencing retinal hypoxia. Because of tissue hypoxia, VEGF expression increases in RPE, pericytes, and microvascular endothelial cells. 22 VEGF induces vessel dilation and increased ocular blood flow through a mechanism involving increased nitric oxide production, 23, 24 and it increases vascular permeability in the eye. 25 Therefore, we speculated that vessel dilation and increased permeability caused by VEGF were related to increased subfoveal choroidal thickness in our study.
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